{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:10:04Z","timestamp":1791609004091,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking. In this work, clinical data of 112 neonates with IH were analyzed retrospectively. All of the patients were evaluated in the hospital at the beginning of the treatment and later in outpatient settings during the treatment. Each time, the following monitoring methods were applied: physical examination, ultrasound echocardiography (UCG), electrocardiography (ECG), blood pressure (BP), heart rate (HR), and basic laboratory tests including blood glucose (BG), liver function, blood potassium, thyroid function. There was a significant reduction in BP and HR at the initiation of treatment. The incidences of bradycardia and hypoglycemia were observed to be increased with the prolong duration of treatment, but not prolonged PR interval. During the course of the therapy, the risk of hyperkalemia and hypothyroidism was reached maximum at the 2\u00a0months and 3\u00a0months, respectively. Physical growth index including average height, weight and head circumference was not influenced by the treatment. The observed adverse effects were majority mild and only 3 patients needed to rest for 7\u00a0days due to severe diarrhea before restarting treatment. This study demonstrated that propranolol is safe and well-tolerated by properly selected young infants with IH. No serious adverse events were observed.<\/jats:p>","DOI":"10.1038\/s41598-023-33105-2","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:04:27Z","timestamp":1681293867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population"],"prefix":"10.1038","volume":"13","author":[{"given":"Ronghua","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingliang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangquan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"33105_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaad.2021.08.019","volume":"85","author":"AI Rodr\u00edguez Bandera","year":"2021","unstructured":"Rodr\u00edguez Bandera, A. I. et al. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. J. Am. Acad. Dermatol. 85, 1379\u20131392. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.019 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"33105_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/PRS.0b013e318208d2ac","volume":"127","author":"CG Bauland","year":"2011","unstructured":"Bauland, C. G. et al. Untreated hemangiomas: Growth pattern and residual lesions. Plast. Reconstr. Surg. 127, 1643\u20131648. https:\/\/doi.org\/10.1097\/PRS.0b013e318208d2ac (2011).","journal-title":"Plast. Reconstr. Surg."},{"key":"33105_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. Infantile haemangioma. Lancet 390, 85\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(16)00645-0 (2017).","journal-title":"Lancet"},{"key":"33105_CR4","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","volume":"136","author":"DH Darrow","year":"2015","unstructured":"Darrow, D. H. et al. Diagnosis and management of infantile hemangioma. Pediatrics 136, e1060-10104. https:\/\/doi.org\/10.1542\/peds.2015-2485 (2015).","journal-title":"Pediatrics"},{"key":"33105_CR5","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 358, 2649\u20132651. https:\/\/doi.org\/10.1056\/NEJMc0708819 (2008).","journal-title":"N. Engl. J. Med."},{"key":"33105_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze, C. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 372, 735\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1404710 (2015).","journal-title":"N. Engl. J. Med."},{"key":"33105_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jpedsurg.2018.08.001","volume":"54","author":"SF Polites","year":"2019","unstructured":"Polites, S. F. et al. Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids. J. Pediatr. Surg. 54, 740\u2013743. https:\/\/doi.org\/10.1016\/j.jpedsurg.2018.08.001 (2019).","journal-title":"J. Pediatr. Surg."},{"key":"33105_CR8","doi-asserted-by":"publisher","first-page":"e20153896","DOI":"10.1542\/peds.2015-3896","volume":"137","author":"S Chinnadurai","year":"2016","unstructured":"Chinnadurai, S., Fonnesbeck, C. & Snyder, K. M. Pharmacologic interventions for infantile hemangioma: A meta-analysis. Pediatrics 137, e20153896. https:\/\/doi.org\/10.1542\/peds.2015-3896 (2016).","journal-title":"Pediatrics"},{"key":"33105_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.jpedsurg.2013.08.020","volume":"48","author":"MA Malik","year":"2013","unstructured":"Malik, M. A. et al. Effect of propranolol vs. prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. J. Pediatr. Surg. 48, 2453\u20132459. https:\/\/doi.org\/10.1016\/j.jpedsurg.2013.08.020 (2013).","journal-title":"J. Pediatr. Surg."},{"key":"33105_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3892\/mco.2021.2318","volume":"15","author":"Y You","year":"2021","unstructured":"You, Y. et al. Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis. Mol. Clin. Oncol. 15, 156. https:\/\/doi.org\/10.3892\/mco.2021.2318 (2021).","journal-title":"Mol. Clin. Oncol."},{"key":"33105_CR11","doi-asserted-by":"publisher","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","volume":"143","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk, D. P. et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics 143, e20183475. https:\/\/doi.org\/10.1542\/peds.2018-3475 (2019).","journal-title":"Pediatrics"},{"key":"33105_CR12","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2011-3683","volume":"130","author":"MM Tollefson","year":"2012","unstructured":"Tollefson, M. M. & Frieden, I. J. Early growth of infantile hemangiomas: What parents\u2019 photographs tell us. Pediatrics 130, e314\u2013e320. https:\/\/doi.org\/10.1542\/peds.2011-3683 (2012).","journal-title":"Pediatrics"},{"key":"33105_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1097\/scs.0000000000004745","volume":"29","author":"MN Xu","year":"2018","unstructured":"Xu, M. N. et al. Individualized treatment for infantile hemangioma. J. Craniofac. Surg. 29, 1876\u20131879. https:\/\/doi.org\/10.1097\/scs.0000000000004745 (2018).","journal-title":"J. Craniofac. Surg."},{"key":"33105_CR14","doi-asserted-by":"publisher","first-page":"e14936","DOI":"10.1111\/dth.14936","volume":"34","author":"N Pam","year":"2021","unstructured":"Pam, N., Kridin, K. & Khamaysi, Z. Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. Dermatol. Ther. 34, e14936. https:\/\/doi.org\/10.1111\/dth.14936 (2021).","journal-title":"Dermatol. Ther."},{"key":"33105_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12519-019-00285-9","volume":"15","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: A meta-analysis of comparative studies. World J. Pediatr. 15, 546\u2013558. https:\/\/doi.org\/10.1007\/s12519-019-00285-9 (2019).","journal-title":"World J. Pediatr."},{"key":"33105_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/pde.14966","volume":"39","author":"JE Gatts","year":"2022","unstructured":"Gatts, J. E. et al. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. Pediatr. Dermatol. 39, 389\u2013393. https:\/\/doi.org\/10.1111\/pde.14966 (2022).","journal-title":"Pediatr. Dermatol."},{"key":"33105_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41598-017-01321-2","volume":"7","author":"Y Ji","year":"2017","unstructured":"Ji, Y. et al. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: A prospective study. Sci. Rep. 7, 1503. https:\/\/doi.org\/10.1038\/s41598-017-01321-2 (2017).","journal-title":"Sci. Rep."},{"key":"33105_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","volume":"174","author":"PH Hoeger","year":"2015","unstructured":"Hoeger, P. H. et al. Treatment of infantile haemangiomas: Recommendations of a European expert group. Eur. J. Pediatr. 174, 855\u2013865. https:\/\/doi.org\/10.1007\/s00431-015-2570-0 (2015).","journal-title":"Eur. J. Pediatr."},{"key":"33105_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/pde.12681","volume":"32","author":"M Hengst","year":"2015","unstructured":"Hengst, M. et al. Blood pressure monitoring during the induction and maintenance period of propranolol therapy for complicated infantile hemangiomas: A prospective study of 109 infants. Pediatr. Dermatol. 32, 802\u2013807. https:\/\/doi.org\/10.1111\/pde.12681 (2015).","journal-title":"Pediatr. Dermatol."},{"key":"33105_CR20","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/adc.63.11.1386","volume":"63","author":"TH Koh","year":"1988","unstructured":"Koh, T. H. et al. Neonatal hypoglycaemia\u2013the controversy regarding definition. Arch. Dis. Child. 63, 1386\u20131388. https:\/\/doi.org\/10.1136\/adc.63.11.1386 (1988).","journal-title":"Arch. Dis. Child."},{"key":"33105_CR21","first-page":"17","volume-title":"Zhu Futang Practice of Pediatrics","author":"Z Jiang","year":"2015","unstructured":"Jiang, Z. & Shen, Y. Zhu Futang Practice of Pediatrics 8th edn, 17\u201321 (People\u2019s Medical Publishing House, 2015).","edition":"8"},{"key":"33105_CR22","doi-asserted-by":"publisher","first-page":"e20160353","DOI":"10.1542\/peds.2016-0353","volume":"138","author":"C L\u00e9aute-Labr\u00e8ze","year":"2016","unstructured":"L\u00e9aute-Labr\u00e8ze, C. et al. Safety of oral propranolol for the treatment of infantile hemangioma: A systematic review. Pediatrics 138, e20160353. https:\/\/doi.org\/10.1542\/peds.2016-0353 (2016).","journal-title":"Pediatrics"},{"key":"33105_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/scs.0000000000003542","volume":"28","author":"M Kado","year":"2017","unstructured":"Kado, M. et al. Successful treatment of infantile hemangiomas with propranolol in low-birth-weight infants. J. Craniofac. Surg. 28, 789\u2013793. https:\/\/doi.org\/10.1097\/scs.0000000000003542 (2017).","journal-title":"J. Craniofac. Surg."},{"key":"33105_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjd.13250","volume":"172","author":"H Song","year":"2015","unstructured":"Song, H. et al. Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. Br. J. Dermatol. 172, 444\u2013449. https:\/\/doi.org\/10.1111\/bjd.13250 (2015).","journal-title":"Br. J. Dermatol."},{"key":"33105_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0196-0644(88)80308-1","volume":"17","author":"GR Gwinup","year":"1988","unstructured":"Gwinup, G. R. Propranolol toxicity presenting with early repolarization, ST segment elevation, and peaked T waves on the ECG. Ann. Emerg. Med. 17, 171\u2013174. https:\/\/doi.org\/10.1016\/s0196-0644(88)80308-1 (1988).","journal-title":"Ann. Emerg. Med."},{"key":"33105_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/17512433.2022.2020638","volume":"15","author":"L Yu","year":"2022","unstructured":"Yu, L. et al. Safety assessment of propranolol for infantile hemangioma: A study in an Asian population. Expert Rev. Clin. Pharmacol. 15, 237\u2013242. https:\/\/doi.org\/10.1080\/17512433.2022.2020638 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"33105_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.13388","volume":"172","author":"Y Ji","year":"2015","unstructured":"Ji, Y. et al. The use of propranolol in the treatment of infantile haemangiomas: An update on potential mechanisms of action. Br. J. Dermatol. 172, 24\u201332. https:\/\/doi.org\/10.1111\/bjd.13388 (2015).","journal-title":"Br. J. Dermatol."},{"key":"33105_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ki.1981.108","volume":"20","author":"RA DeFronzo","year":"1981","unstructured":"DeFronzo, R. A. et al. Epinephrine and potassium homeostasis. Kidney Int. 20, 83\u201391. https:\/\/doi.org\/10.1038\/ki.1981.108 (1981).","journal-title":"Kidney Int."},{"key":"33105_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/(sici)1520-6017(200005)89:5<586::Aid-jps4>3.0.Co;2-6","volume":"89","author":"PJ Gow","year":"2000","unstructured":"Gow, P. J. et al. Neonatal hepatic propranolol elimination: Studies in the isolated perfused neonatal sheep liver. J. Pharm. Sci. 89, 586\u2013593. https:\/\/doi.org\/10.1002\/(sici)1520-6017(200005)89:5%3c586::Aid-jps4%3e3.0.Co;2-6 (2000).","journal-title":"J. Pharm. Sci."},{"key":"33105_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-198308010-00001","volume":"8","author":"J Feely","year":"1983","unstructured":"Feely, J. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease. Clin. Pharmacokinet. 8, 1\u201316. https:\/\/doi.org\/10.2165\/00003088-198308010-00001 (1983).","journal-title":"Clin. Pharmacokinet."},{"key":"33105_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.mayocp.2018.10.011","volume":"94","author":"A Sharma","year":"2019","unstructured":"Sharma, A. & Stan, M. N. Thyrotoxicosis: Diagnosis and management. Mayo Clin. Proc. 94, 1048\u20131064. https:\/\/doi.org\/10.1016\/j.mayocp.2018.10.011 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"33105_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2016.02.1218","volume":"75","author":"AV Moyakine","year":"2016","unstructured":"Moyakine, A. V. et al. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J. Am. Acad. Dermatol. 75, 59-63.e1. https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1218 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"33105_CR33","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/1346-8138.13324","volume":"43","author":"L Hu","year":"2016","unstructured":"Hu, L. et al. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. J. Dermatol. 43, 1160\u20131166. https:\/\/doi.org\/10.1111\/1346-8138.13324 (2016).","journal-title":"J. Dermatol."},{"key":"33105_CR34","doi-asserted-by":"publisher","first-page":"2728952","DOI":"10.1155\/2019\/2728952","volume":"2019","author":"X Li","year":"2019","unstructured":"Li, X. et al. Propranolol treatment for infantile hemangiomas: Short-term adverse effects and follow-up to age two. Biomed. Res. Int. 2019, 2728952. https:\/\/doi.org\/10.1155\/2019\/2728952 (2019).","journal-title":"Biomed. Res. Int."},{"key":"33105_CR35","doi-asserted-by":"publisher","first-page":"e20173783","DOI":"10.1542\/peds.2017-3783","volume":"141","author":"C Droitcourt","year":"2018","unstructured":"Droitcourt, C. et al. Safety of oral propranolol for infantile hemangioma. Pediatrics 141, e20173783. https:\/\/doi.org\/10.1542\/peds.2017-3783 (2018).","journal-title":"Pediatrics"},{"key":"33105_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jama.2015.13969","volume":"315","author":"S Prey","year":"2016","unstructured":"Prey, S. et al. Safety of propranolol therapy for severe infantile hemangioma. JAMA 315, 413\u2013415. https:\/\/doi.org\/10.1001\/jama.2015.13969 (2016).","journal-title":"JAMA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33105-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:14:43Z","timestamp":1681294483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33105-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33105"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33105-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5956"}}